MDS Capital

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Usystems specializes in the design, development, and manufacture of advanced ultrasound systems and software aimed at enhancing breast cancer detection, particularly in women with dense breast tissue. The company's innovative products provide high-quality 3D ultrasound images that assist radiologists in identifying areas of concern within breast tissue. In addition to its focus on medical imaging, Usystems is dedicated to creating cutting-edge racking enclosures and cooling solutions that minimize noise, heat, and operational costs in data centers and office environments. Through a commitment to quality and innovation, Usystems employs state-of-the-art manufacturing processes to deliver effective solutions in both healthcare and data management sectors.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for unmet medical needs. Founded by experienced pharmaceutical executives, the company is engaged in creating new drugs and treatments for challenging illnesses. Its product portfolio includes Reslizumab, which is aimed at treating eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents that have the potential for oral administration. Additionally, Ception's offerings encompass treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. The company's research pipeline focuses on developing new compounds and expanding indications for existing therapies.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Resonant Medical is a company that develops, manufactures, and commercializes 3D ultrasound image-guided adaptive radiotherapy products aimed at improving radiation therapy for cancer patients. Its product offerings include the Clarity Breast System, which provides non-ionizing guidance for breast treatments; the Clarity Prostate System, designed for precise non-invasive guidance in prostate cancer treatments; and the Multi-Anatomy System, which facilitates image-guided treatments for various soft tissue anatomies, including gynecological and bladder applications. Established in 2000 and headquartered in Montreal, Canada, Resonant Medical serves a diverse range of healthcare professionals, including physicians, physicists, and therapists. The company's innovative platform enhances radiation therapy planning, verification, and delivery, ensuring advanced care without the use of radiation, thus addressing critical clinical needs in cancer treatment.

Adnavance Technologies is an early-stage developer of direct detection molecular diagnostic tests. The company's patented and ultra-sensitive metalized-DNA (M-DNAâ„¢) technology may eliminate the need for amplification for a large number of these tests. This technology provides many significant advantages over existing methods, including ease of use, time to result and cost. The platform is simple and inexpensive and is expected to receive FDA approval for use by any laboratory.

Guava Technologies, Inc. is a manufacturer of biotechnology and medical devices, specializing in the development and design of products for life science research and clinical diagnostics. The company provides a range of solutions, including flow cytometry systems and assays for cell counting, viability, antibody quantification, apoptosis, and cytotoxicity. These products support various applications in cell biology research and drug discovery, with a particular emphasis on HIV/AIDS monitoring. Founded in 1998 and headquartered in Hayward, California, Guava Technologies operates as a subsidiary of Millipore Corp.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

Inimex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, specializing in the development and commercialization of Innate Defense Regulators (IDRs). These innovative drugs are designed to selectively modulate the body's innate immune defenses without inducing inflammation. The company's lead product, IMX942, aims to enhance survival rates, reduce tissue damage, and mitigate bacterial infections. Inimex's IDR products target a range of medical conditions, including infections and tissue injury-related ailments such as ventilator-associated pneumonia, tracheobronchitis, bacteremia, endocarditis, mucositis, and certain cancers. Founded in 2001, Inimex Pharmaceuticals is dedicated to advancing its unique therapies to improve patient outcomes.

ViOptix, Inc. specializes in developing and manufacturing innovative tissue oximetry technology that measures local tissue oxygen saturation. Its primary product, the T.Ox Tissue Oximeter, is a lightweight and portable device featuring a color LCD touchscreen, capable of supporting one or two fiber optic sensors. The company also offers remote monitoring solutions that enable wireless data transmission to various internet-connected devices and provides single-use, pre-sterilized sensors for continuous monitoring. ViOptix's technology is applicable in various medical fields, including plastic surgery, critical care, and oncology, where it assists in assessing tissue viability, estimating wound healing potential, and monitoring oxygen saturation during and after surgical procedures. Founded in 1999 and headquartered in Fremont, California, ViOptix was previously known as Photonify Technologies, Inc. and adopted its current name in 2003.

Pharmasset Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative drugs for viral infections. The company specializes in oral therapeutics targeting hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Its research centers on nucleoside analogs, which inhibit enzymes essential for viral replication. Pharmasset is advancing three product candidates: Clevudine, aimed at HBV, which is expected to enter Phase 3 clinical trials; R7128, a pro-drug for HCV currently in Phase 1 trials; and Racivir, an investigational treatment for HIV in Phase 2 trials. Through these efforts, Pharmasset seeks to provide effective treatment options for patients suffering from these viral infections.

Alveolus specializes in non-vascular interventional stenting technology aimed at providing innovative solutions for pulmonary and gastrointestinal applications, as well as ancillary products. The company develops advanced stents that create artificial pathways and support structures for hollow organs that have become obstructed due to cancerous lesions or benign conditions. By offering these technologies, Alveolus enhances the capabilities of interventional pulmonologists, gastroenterologists, and radiologists, facilitating improved treatment options for patients facing these medical challenges.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Renovis, Inc. is a biopharmaceutical company focused on the development of drugs for neurological diseases and disorders. The company is actively working on treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing a range of scientific disciplines, including molecular biology, medicinal chemistry, pharmacology, drug metabolism, toxicology, and informatics, Renovis aims to identify and select small molecule drug candidates that adhere to rigorous development standards.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has potential applications across various sectors, including oncology, infectious disease diagnosis, organ transplantation, reproductive health, genetic testing, and forensics.

TriVirix International is a U.S.-based manufacturer and designer of electro-mechanical medical devices, diagnostic tools, and life-science equipment. Headquartered in Milaca, Minnesota, the company specializes in producing a range of products, including ribo printers, point-of-care blood testing analyzers, volumetric infusion pumps, and vital sign monitors. TriVirix International focuses on delivering innovative solutions for the healthcare industry, addressing the needs of medical professionals and enhancing patient care through advanced technology.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

Alveolus specializes in non-vascular interventional stenting technology aimed at providing innovative solutions for pulmonary and gastrointestinal applications, as well as ancillary products. The company develops advanced stents that create artificial pathways and support structures for hollow organs that have become obstructed due to cancerous lesions or benign conditions. By offering these technologies, Alveolus enhances the capabilities of interventional pulmonologists, gastroenterologists, and radiologists, facilitating improved treatment options for patients facing these medical challenges.

Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cardio-renal diseases. The company's product pipeline features adenosine agonists and antagonists aimed at treating cardiovascular conditions, alongside leukotriene synthesis inhibitors for chronic renal diseases. Aderis focuses on creating small-molecule, receptor-specific therapeutics that modulate the activity of proteins like adenosine and dopamine, thereby enhancing therapeutic effects while reducing side effects. Additionally, Aderis has established license agreements with strategic partners for advanced products targeting Parkinson's disease and for the diagnosis of coronary artery disease.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada.

Salu, Inc. was founded in 1997 to help physician specialists and is currently the premier company creating vertical Internet healthcare "hubs" in the specialty physician market. The Salu Hub, formed on a specialty-by-specialty basis, facilitates daily interaction among physicians, patients and industry partners and provides relevant information, services and products for all Hub participants. The Salu Hub connects these parties and simplifies interaction, communication, information delivery and receipt and the purchase of medical goods and services. Salu allows specialty physicians to leverage the Web to benefit their practices and their relationships with their patients. This approach has resulted in more than 17,000 specialty physician-members registering for Salu services including 50 percent of office-based allergists, 17 percent of cardiologists, 11 percent of pulmonologists and 17 percent of physiatrists in the U.S.

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.